ArticleOpen heart2025
Treatment disparities and prognostic implications in octogenarians versus non-octogenarians with high-gradient severe aortic stenosis.
Article in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAortic valve replacement (AVR) is considered one of the most potent disease-modifying procedures among patients with severe aortic stenosis (sAS). Accordingly, we have witnessed a consistent increase in the procedure rates in recent years. Nevertheless, the elderly population, particularly octogenarians, remains relatively undertreated. The current study aims to document the disparities in AVR rates among octogenarians and its prognostic significance.
methodsA vast database of Maccabi Health Services, the second largest health maintenance organisation in Israel, counting nearly 2.8 million members, was retrospectively analysed from 2005 to 2021 for all patients over 60 years, with a detailed echocardiography report compatible with a diagnosis of high-gradient sAS. The database was extracted using the MDClone healthcare data platform, generating synthetic data reliably representing the original population. All-cause mortality was set to be the primary outcome, and survival models using adjusted multivariable analyses for several clinical and echocardiographic parameters were applied.
resultsThe cohort consisted of 1396 patients with high-gradient sAS (76±7 years) with 39% octogenarians. Octogenarians were less likely to undergo AVR (42% vs 60%, p<0.01) and presented more severe clinical profiles. AVR significantly reduced mortality and hospitalisations in both age groups, but octogenarians showed a pronounced survival benefit regardless of symptom status. A time-dependent analysis showed that AVR was associated with reduced all-cause mortality (HR 0.30, 95% CI 0.23 to 0.41, p<0.001) within the octogenarian group in 5 years. A similar protective effect was shown in the non-octogenarian group (HR 0.32, 95% CI 0.22 to 0.46, p<0.001).
conclusionThis study highlights significant treatment disparities in AVR among octogenarians with high-gradient sAS despite clear benefits in survival and reduced hospitalisations. The findings suggest the need for more inclusive treatment strategies, particularly for older patients, and underscore the importance of AVR in improving clinical outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.